FDA Alerts

FDA approves Evkeeza for young children with ultra-rare form of high cholesterol

The U.S. Food and Drug Administration has extended the approval of evinacumab-dgnb (Evkeeza; Regeneron) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), according to a press release. Evinacumab was approved in February 2021 as an adjunct to other lipid-lowering...